Silodosin is a novel alpha-1 adrenergic receptor antagonist that has been shown to be effective and safe for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. It has greater selectivity for the alpha-1A receptor compared to other drugs, does not affect blood pressure or heart rate, and improves IPSS and urine flow rates when taken at 8 mg daily. Retrograde ejaculation is the most common side effect but few patients discontinue treatment due to this. Silodosin has efficacy and cardiovascular safety, making it a good treatment option for an aging population.
Original Description:
Original Title
IUA 2015 Soebadi DM Update on medical management of BPH
Silodosin is a novel alpha-1 adrenergic receptor antagonist that has been shown to be effective and safe for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. It has greater selectivity for the alpha-1A receptor compared to other drugs, does not affect blood pressure or heart rate, and improves IPSS and urine flow rates when taken at 8 mg daily. Retrograde ejaculation is the most common side effect but few patients discontinue treatment due to this. Silodosin has efficacy and cardiovascular safety, making it a good treatment option for an aging population.
Silodosin is a novel alpha-1 adrenergic receptor antagonist that has been shown to be effective and safe for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. It has greater selectivity for the alpha-1A receptor compared to other drugs, does not affect blood pressure or heart rate, and improves IPSS and urine flow rates when taken at 8 mg daily. Retrograde ejaculation is the most common side effect but few patients discontinue treatment due to this. Silodosin has efficacy and cardiovascular safety, making it a good treatment option for an aging population.
Update on medical management of BPH: focusing on safety.
Prof. Doddy M. Soebadi, MD, PhD
Dept. of Urology, Universitas Airlangga - Soetomo General Hospital Surabaya - Indonesia
Abstract
Alpha1-adrenergic receptor antagonists are commonly used to treat male
LUTS and BPH. It is well known that a-blockers have different levels of selectivity, and, from this perspective, tamsulosin is the only alpha1-receptor antagonist that has demonstrated a pronounced preferential selectivity for the a1A-receptor rather than the alpha1B or alpha1D receptors (some 10–15 times more selective). Silodosin is a novel alpha1-adrenergic receptor antagonist whose affinity for the alpha1A-adrenergic receptor is greater than that for the α1B-adrenergic receptor. Silodosin seemed not to affect the blood pressure and heart rate compared to the placebo. Silodosin at a daily dose of 8 mg was effective, improving the IPSS and Q max. Silodosin was also safe and effective in the long-term treatment of nocturia. Retrograde or abnormal ejaculation was the most commonly reported side effect in the patients treated with silodosin, however, discontinuation of Phase III studies due to abnormal ejaculation was relatively low. Evidence showing solid efficacy and cardiovascular safety profiles of silodosin will provide a good solution for the treatment of LUTS associated with BPH in an increasingly aging society.